Comparison of the microarray-based assay, the real-time PCR assay, and the bidirectional sequencing method for CYP2C19 genotyping

Background: Cytochrome P450 2C19 (CYP2C19) is a clinically important enzyme that metabolizes a wide variety of drugs. Recently, some new genetic assays designed to identify the CYP2C19 genotype were introduced. Methods: We compared the abilities of the microarray-based Verigene CYP2C19 Test (Nanosphere, USA) and the AccuPower Real-time PCR CYP (^∗2,^∗3,^∗17) assay (Bioneer, Korea) with the ability of the bidirectional sequencing method for the detection of CYP2C19 genotypes in 78 whole blood samples. Results: Among 78 specimens, 28 were ^∗1/^∗1, 1 was ^∗1/^∗17, 27 were ^∗1/^∗2, 10 were ^∗1/^∗3, 8 were ^∗2/^∗2, 1 was ^∗3/^∗3, and 3 were ^∗2/^∗3. In the initial test, five samples (6.4%) in the Verigene assay and two samples (2.4%) in the AccuPower assay failed to generate definite results. All retests with both assays generated definitive results. In both assays, the results of CYP2C19 genotyping showed 100% final concordance with those obtained by the direct sequencing method. Conclusions: These two assays could be useful for the identification of CYP2C19 genotypes in clinical laboratories.